Mukesh Mukesh B, Qian Wendi, Wilkinson Jennifer S, Dorling Leila, Barnett Gillian C, Moody Anne M, Wilson Charles, Twyman Nicola, Burnet Neil G, Wishart Gordon C, Coles Charlotte E
Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, UK; Department of Oncology, Colchester Hospital University NHS Foundation Trust, Essex, UK.
Cambridge Cancer Trials Centre, Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Medical Research Council, Biostatistics Unit Hub for Trials Methodology, UK.
Radiother Oncol. 2014 May;111(2):270-5. doi: 10.1016/j.radonc.2014.02.016. Epub 2014 Apr 16.
The use of intensity-modulated radiotherapy (IMRT) in breast cancer reduces clinician-assessed breast tissue toxicity including fibrosis, telangectasia and sub-optimal cosmesis. Patient reported outcome measures (PROMs) are also important as they provide the patient's perspective. This longitudinal study reports on (a) the effect of forward planned field-in-field IMRT (∼simple IMRT) on PROMs compared to standard RT at 5 years after RT, (b) factors affecting PROMs at 5years after RT and (c) the trend of PROMs over 5 years of follow up.
PROMs were assessed at baseline (pre-RT), 6, 24 and 60 months after completion of RT using global health (EORTC QLQ C30) and 4 breast symptom questions (BR23). Also, 4 breast RT-specific questions were included at 6, 24 and 60 months: change in skin appearance, firmness to touch, reduction in breast size and overall change in breast appearance since RT. The benefits of simple IMRT over standard RT at 5 years after RT were assessed using standard t-test for global health and logistic regression analysis for breast symptom questions and breast RT-specific questions. Clinical factors affecting PROMs at 5 years were investigated using a multivariate analysis. A repeated mixed model was applied to explore the trend over time for each of PROMs.
(89%) 727/815, 84%, 81% and 61% patients completed questionnaires at baseline, 6, 24 and 60 months respectively. Patients reported worse toxicity for all four BR23 breast symptoms at 6 months, which then improved over time (p<0.0001). They also reported improvement in skin appearance and breast hardness over time (p<0.0001), with no significant change for breast shrinkage (p=0.47) and overall breast appearance (p=0.13). At 5years, PROMs assessments did not demonstrate a benefit for simple IMRT over standard radiotherapy. Large breast volume, young age, baseline surgical cosmesis and post-operative infection were the most important variables to affect PROMs.
This study was unable to demonstrate the benefits of IMRT on PROMs at 5years. PROMs are influenced by non-radiotherapy factors and surgical factors should be optimised to improve patients' outcome. Only a small proportion of patients report moderate-severe breast changes post radiotherapy, with most PROMs improving over time. The difference in clinician assessment and PROMs outcome requires further investigation.
在乳腺癌治疗中使用调强放射治疗(IMRT)可降低临床医生评估的乳腺组织毒性,包括纤维化、毛细血管扩张和不理想的美容效果。患者报告结局指标(PROMs)也很重要,因为它们提供了患者的观点。这项纵向研究报告了:(a)与标准放疗相比,正向计划的野中野IMRT(即简易IMRT)在放疗后5年对PROMs的影响;(b)放疗后5年影响PROMs的因素;(c)随访5年期间PROMs的变化趋势。
在基线(放疗前)、放疗结束后6个月、24个月和60个月使用总体健康状况(欧洲癌症研究与治疗组织QLQ C30)和4个乳腺症状问题(BR23)评估PROMs。此外,在6个月、24个月和60个月还纳入了4个乳腺放疗特异性问题:皮肤外观变化、触摸时的硬度、乳房大小减小以及放疗后乳房外观的总体变化。使用标准t检验评估简易IMRT相对于标准放疗在放疗后5年的益处,对乳腺症状问题和乳腺放疗特异性问题使用逻辑回归分析。使用多变量分析研究放疗后5年影响PROMs的临床因素。应用重复混合模型探索每个PROMs随时间的变化趋势。
分别有727/815(89%)、84%、81%和61%的患者在基线、6个月、24个月和60个月完成了问卷调查。患者报告在6个月时所有四个BR23乳腺症状的毒性更严重,随后随时间改善(p<0.0001)。他们还报告随着时间推移皮肤外观和乳房硬度有所改善(p<0.0001),乳房缩小(p=0.47)和乳房总体外观无显著变化(p=0.13)。在5年时,PROMs评估未显示简易IMRT相对于标准放疗有优势。大乳房体积、年轻、基线手术美容效果和术后感染是影响PROMs的最重要变量。
本研究未能证明IMRT在5年时对PROMs有优势。PROMs受非放疗因素影响,应优化手术因素以改善患者结局。只有一小部分患者报告放疗后有中度至重度乳腺变化,大多数PROMs随时间改善。临床医生评估与PROMs结果的差异需要进一步研究。